Delivery Time: 5-10 Days
Payment Terms: T/T, Western Union, Moneygram, Bitcoin
Minimum Order: 10g
Storage: Shading, Confined Preservation
Appearance: White Powder
MW: 446.9
Mf: C22h24clfn4o3
Policy: Re-Shipping Policy
Specifications: 99% Purity
Supply Ability: 5000kg Per Month
Trademark: JZY
Transport Package: Disguised Package
Specification: White powder
Origin: China
Delivery Time: 5-10 Days
Payment Terms: T/T, Western Union, Moneygram, Bitcoin
Minimum Order: 10g
Storage: Shading, Confined Preservation
Appearance: White Powder
MW: 446.9
Mf: C22h24clfn4o3
Policy: Re-Shipping Policy
Specifications: 99% Purity
Supply Ability: 5000kg Per Month
Trademark: JZY
Transport Package: Disguised Package
Specification: White powder
Origin: China

Â
Product Name: | Gefitini |
Synonyms: | IRESS;GEFITINI;AKOS 91371;n-(3-chloro-4-fluoro-phenyl)-7-methoxy-6-(3-morpholin-4-ylpropoxy)quinazolin-4-amine;N-(3-Chloro-4-fluorophenyl)-7-methoxy-6-[3-(4-morpholinyl)propoxy]-4-quinazolinamine;ZD 1839;4-Quinazolinamine, N-(3-chloro-4-fluorophenyl)-7-methoxy-6-[3-(4-morpholinyl)propoxy]-;Gefitini(TINIBS) |
CAS: | Â |
MF: | C22H24ClFN4O3 |
MW: | 446.9 |
EINECS: | Â |
Product Categories: | Active Pharmaceutical Ingredients;Gefitini;Molecular Targeted Antineoplastic;Intermediates &Â Fine Chemicals;Pharmaceuticals;Pharmaceutical intermediate;APIs;IRESS;Anti-cancer&immunity;API;Inhibitors |
Mol File: | Â |
Chemical Properties | Light-Yellow Crystalline Powder |
Usage | Gefitini (Iress, ZD-1839) is an EGFR inhibitor for Tyr1173, Tyr992, Tyr1173 and Tyr992 in the NR6wtEGFR and NR6W cells with IC50 of 37 nM, 37nM, 26 nM and 57 nM, respectively. |
Usage | Gefitini is an antineoplastic. |
Biological Activity | Orally active, selective inhibitor of EGFR tyrosine kinase (IC 50 = 23-79 nM). Shows minimal activity against ErbB2, KDR, c-flt, PKC, MEK and ERK-2. Blocks EGFR autophosphorylation and inhibits tumor growth in mice bearing a range of human xenografts. |
General introduction:
Gefitini, is a drug used for certain breast, lung , and other cancers, also known as Iress, a selective epidermal  receptor (EGFR) tyrosine kinase inhibitor, for the treatment of prior locally advanced or metastatic non-chemical treatment or unsuitable for chemotherapysmall cell lung cancer (NSCLC).
Gefitini is the first selective inhibitor of epidermal  receptor's (EGFR) tyrosine kinase domain. Thus gefitini is an EGFR inhibitor. The target protein (EGFR) is a family of receptors which includes Her1(erb-B1), Her2(erb-B2), and Her 3(erb-B3). EGFR is overexpressed in the cells of certain types of human carcinomas - for example in lung and breast cancers. This leads to inappropriate activation of the anti-apoptotic Ras signalling cascade, eventually leading to uncontrolled cell proliferation. Research on gefitini-sensitive non-small cell lung cancers has shown that a mutation in the EGFR tyrosine kinase domain is responsible for activating anti-apoptotic pathways. These mutations tend to confer increased sensitivity to tyrosine kinase inhibitors such as gefitini and erlotinib. Of the types of non-small cell lung cancer histologies, adenocarcinoma is the type that most often harbors these mutations. These mutations are more commonly seen in Asians, women, and non-smokers (who also tend to more often have adenocarcinoma).
Gefitini inhibits EGFR tyrosine kinase by binding to the adenosine triphosphate (ATP)-binding site of the enzyme. Thus the function of the EGFR tyrosine kinase in activating the anti-apoptotic Ras signal transduction cascade is inhibited, and malignant cells are inhibited.
Gefitini Usage:
Â
Gefitini is a kind of selective inhibitor of the epidermal receptor (EGFR) tyrosine kinase.
The recommended treatment dose of adult is 250 mg of (1 tablet) with 1Â time per day through orally administration, either in empty stomach or together with food.
If you have difficulty in swallowing, you can disperse the tablets into a half cup of drinking water (non-carbonated beverages). Make sure to avoid using other kinds of liquid. Cast tablets into the water and stir until the complete dispersion of the tablet in the water (takes about 10 minutes) without the necessity of crushing. Immediately drink the liquid, and use half glass of water to rinse the cup, drink again. Alternatively, you can also administrate this drug solution through the nose-stomach tube.
There is no necessity in adjusting the administrated dosage of the drug: age, weight, gender, race, renal function, and moderate to severe liver function dysfunction caused by hepatic metastasis.
Dose adjustment: when patients can't tolerate the diarrhea or skin adverse reactions, you can tackle this issue through short-term suspension (up to 14 days) of the treatment and then restore the dose of 250 mg per day.
Â
Chemical Properties Light-Yellow Crystalline Powder
Usage Gefitini (Iress, ZD-1839) is an EGFR inhibitor for Tyr1173, Tyr992, Tyr1173 and Tyr992 in the NR6wtEGFR and NR6W cells with IC50 of 37 nM, 37nM, 26 nM and 57 nM, respectively.
Usage Gefitini is an antineoplastic.
Â
Gefitini Side effects:
Â
It has a better tolerability with most adverse reaction being minor and reversible, and is totally different from typical adverse reactions of cytotoxic drugs. Common adverse reactions include diarrhea, nausea, rashes, acne, vomiting and weakness with the incidence being over 20%. The ratio of patents who stops the treatment because of the adverse drug reactions is only 1%. Sometimes acute interstitial pneumonia can happen occasionally which can even cause death of some patients. Therefore, if enhanced respiratory symptoms such as shortness of breath, cough and fever happen in the patients, should immediately discontinue the treatment, and find out whether it is interstitial pneumonia. Gefitini is not suitable for applied to women during pregnancy. Lactation women should stop breastfeeding during the treatment.
COA:
Â
Product name |
 Gefitini  |
||
CAS No. |
  |
Outer Packing |
 1KG  |
Production date | Â May,05,2016 |
Shelf life | Â May.04,2019 |
Standard adopted | Â Â house standard |
||
Items of analysis | Specification | Results | |
  Appearance |
  White to off-white powder |
  off-White powder |
|
  Identifcation |
  HPLC(RT) |
  Complies |
|
  Loss on drying |
  ≤ 0.5% |
  0.13% |
|
  Residue on ignition |
  ≤0.,1% |
  0.1% |
|
  Max Single Impurity |
  ≤ 0.10 % |
  0.09% |
|
  Total Impurity |
  ≤.1.0% |
  0.24% |
|
  Purity(HPLC) |
  ≥99% |
  99.76% |
|
Conclusion | Qualified |
Â

Â
Product Name: | Gefitini |
Synonyms: | IRESS;GEFITINI;AKOS 91371;n-(3-chloro-4-fluoro-phenyl)-7-methoxy-6-(3-morpholin-4-ylpropoxy)quinazolin-4-amine;N-(3-Chloro-4-fluorophenyl)-7-methoxy-6-[3-(4-morpholinyl)propoxy]-4-quinazolinamine;ZD 1839;4-Quinazolinamine, N-(3-chloro-4-fluorophenyl)-7-methoxy-6-[3-(4-morpholinyl)propoxy]-;Gefitini(TINIBS) |
CAS: | Â |
MF: | C22H24ClFN4O3 |
MW: | 446.9 |
EINECS: | Â |
Product Categories: | Active Pharmaceutical Ingredients;Gefitini;Molecular Targeted Antineoplastic;Intermediates &Â Fine Chemicals;Pharmaceuticals;Pharmaceutical intermediate;APIs;IRESS;Anti-cancer&immunity;API;Inhibitors |
Mol File: | Â |
Chemical Properties | Light-Yellow Crystalline Powder |
Usage | Gefitini (Iress, ZD-1839) is an EGFR inhibitor for Tyr1173, Tyr992, Tyr1173 and Tyr992 in the NR6wtEGFR and NR6W cells with IC50 of 37 nM, 37nM, 26 nM and 57 nM, respectively. |
Usage | Gefitini is an antineoplastic. |
Biological Activity | Orally active, selective inhibitor of EGFR tyrosine kinase (IC 50 = 23-79 nM). Shows minimal activity against ErbB2, KDR, c-flt, PKC, MEK and ERK-2. Blocks EGFR autophosphorylation and inhibits tumor growth in mice bearing a range of human xenografts. |
General introduction:
Gefitini, is a drug used for certain breast, lung , and other cancers, also known as Iress, a selective epidermal  receptor (EGFR) tyrosine kinase inhibitor, for the treatment of prior locally advanced or metastatic non-chemical treatment or unsuitable for chemotherapysmall cell lung cancer (NSCLC).
Gefitini is the first selective inhibitor of epidermal  receptor's (EGFR) tyrosine kinase domain. Thus gefitini is an EGFR inhibitor. The target protein (EGFR) is a family of receptors which includes Her1(erb-B1), Her2(erb-B2), and Her 3(erb-B3). EGFR is overexpressed in the cells of certain types of human carcinomas - for example in lung and breast cancers. This leads to inappropriate activation of the anti-apoptotic Ras signalling cascade, eventually leading to uncontrolled cell proliferation. Research on gefitini-sensitive non-small cell lung cancers has shown that a mutation in the EGFR tyrosine kinase domain is responsible for activating anti-apoptotic pathways. These mutations tend to confer increased sensitivity to tyrosine kinase inhibitors such as gefitini and erlotinib. Of the types of non-small cell lung cancer histologies, adenocarcinoma is the type that most often harbors these mutations. These mutations are more commonly seen in Asians, women, and non-smokers (who also tend to more often have adenocarcinoma).
Gefitini inhibits EGFR tyrosine kinase by binding to the adenosine triphosphate (ATP)-binding site of the enzyme. Thus the function of the EGFR tyrosine kinase in activating the anti-apoptotic Ras signal transduction cascade is inhibited, and malignant cells are inhibited.
Gefitini Usage:
Â
Gefitini is a kind of selective inhibitor of the epidermal receptor (EGFR) tyrosine kinase.
The recommended treatment dose of adult is 250 mg of (1 tablet) with 1Â time per day through orally administration, either in empty stomach or together with food.
If you have difficulty in swallowing, you can disperse the tablets into a half cup of drinking water (non-carbonated beverages). Make sure to avoid using other kinds of liquid. Cast tablets into the water and stir until the complete dispersion of the tablet in the water (takes about 10 minutes) without the necessity of crushing. Immediately drink the liquid, and use half glass of water to rinse the cup, drink again. Alternatively, you can also administrate this drug solution through the nose-stomach tube.
There is no necessity in adjusting the administrated dosage of the drug: age, weight, gender, race, renal function, and moderate to severe liver function dysfunction caused by hepatic metastasis.
Dose adjustment: when patients can't tolerate the diarrhea or skin adverse reactions, you can tackle this issue through short-term suspension (up to 14 days) of the treatment and then restore the dose of 250 mg per day.
Â
Chemical Properties Light-Yellow Crystalline Powder
Usage Gefitini (Iress, ZD-1839) is an EGFR inhibitor for Tyr1173, Tyr992, Tyr1173 and Tyr992 in the NR6wtEGFR and NR6W cells with IC50 of 37 nM, 37nM, 26 nM and 57 nM, respectively.
Usage Gefitini is an antineoplastic.
Â
Gefitini Side effects:
Â
It has a better tolerability with most adverse reaction being minor and reversible, and is totally different from typical adverse reactions of cytotoxic drugs. Common adverse reactions include diarrhea, nausea, rashes, acne, vomiting and weakness with the incidence being over 20%. The ratio of patents who stops the treatment because of the adverse drug reactions is only 1%. Sometimes acute interstitial pneumonia can happen occasionally which can even cause death of some patients. Therefore, if enhanced respiratory symptoms such as shortness of breath, cough and fever happen in the patients, should immediately discontinue the treatment, and find out whether it is interstitial pneumonia. Gefitini is not suitable for applied to women during pregnancy. Lactation women should stop breastfeeding during the treatment.
COA:
Â
Product name |
 Gefitini  |
||
CAS No. |
  |
Outer Packing |
 1KG  |
Production date | Â May,05,2016 |
Shelf life | Â May.04,2019 |
Standard adopted | Â Â house standard |
||
Items of analysis | Specification | Results | |
  Appearance |
  White to off-white powder |
  off-White powder |
|
  Identifcation |
  HPLC(RT) |
  Complies |
|
  Loss on drying |
  ≤ 0.5% |
  0.13% |
|
  Residue on ignition |
  ≤0.,1% |
  0.1% |
|
  Max Single Impurity |
  ≤ 0.10 % |
  0.09% |
|
  Total Impurity |
  ≤.1.0% |
  0.24% |
|
  Purity(HPLC) |
  ≥99% |
  99.76% |
|
Conclusion | Qualified |
Â
Freeze-dried powder is a sterile powder injection obtained by freezing the liquid medicine into a solid state in a sterile environment, and subliming and drying the water in a vacuum. Freeze-dried powder is composed of a bottle of high-purity and high-active biological protein freeze-dried powder and a high-purity liquid essence. When using, it needs to be connected with a patented vacuum to reconstitute the freeze-dried powder and the essence to activate the biological protein activity.
Freeze Dried Fruit Powder,Strawberry Powder,Freeze Dried Powder,Raspberry Powder
YT(Xi'an) Biochem Co., Ltd. , https://www.ytherblifes.com